Fairvalue-Calculator Fairvalue-Calculator
EN DE

Jacobio Pharmaceuticals Group (JBPHF) Fair Value & Analysis

Healthcare · US · Market cap $680M

Price$0.8677
Fair Value$0.6500
Upside-25.1%
Quality95/100
Evidence: Low Range $0.4900 – $0.8100

Fair value as of: Jun 24, 2026

Analysis

Jacobio Pharmaceuticals Group (JBPHF) currently trades at $0.8677, while our model-based Fair Value estimate is $0.6500 — implying the stock looks roughly 25.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies in the People's Republic of China. The company develops sitneprotafib (JAB-3312), an oral allosteric SHP2 inhibitor that is in a Phase III trial for non-small cell lung cancer (NSCLC); glecirasib (JAB-21822), a KRAS G12C allosteric inhibitor in Phase II trials for NSCLC, multi-tumor basket, and colorectal cancer; JAB-8263, a BET inhibitor that is in a Phase IIa trial for solid tumors and hematologic malignancies; JAB-BX102, a humanized monoclonal antibody against CD73, which is in a Phase I/IIa trial; JAB-2485, a highly selective Aurora Kinase A (AURKA) inhibitor that is in a Phase I/IIa trial for solid tumors; JAB-23E73, an oral small-molecule pan-KRAS inhibitor that is in a Phase I trial for KRAS-mutant PDAC, CRC, NSCLC, and solid tumors; and JAB-30355, a bioavailable small molecule p53 reactivator that is in a Phase I trial for the treatm…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is Jacobio Pharmaceuticals Group (JBPHF) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $0.6500 versus a price of $0.8677 — about −25% (overvalued). Model-based estimate, not financial advice.
What is the fair value of JBPHF?
Our 21-model fair value for Jacobio Pharmaceuticals Group is $0.6500 (as of Jun 24, 2026), built from audited fundamentals. The current price is $0.8677.
What is the quality score of JBPHF?
Jacobio Pharmaceuticals Group has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.